Development of Genetically Modified Tumor Cell Containing Co-stimulatory Molecule

  • Kim, Hong Sung (Department of Biomedical Laboratory Science, Korea Nazarene University)
  • Received : 2019.12.24
  • Accepted : 2019.12.24
  • Published : 2019.12.31


Cancer immunotherapy using gene-modified tumor cells is safe and customized cancer treatment method. In this study, we made gene-modified tumor cells by transferring costimulatory molecules, 4-1BBL and OX40L, into tumor cells using lentivirus vector, and identified anti-cancer effect of gene-modified tumor cells in CT26 mouse colorectal tumor model. We construct pLVX-puro-4-1BBL, -OX40L vector for lentivirus production and optimized the transfection efficiency and transduction efficiency. The transfection efficiency is maximal at DNA:cationic polymer = 1:0.5 and DNA 2 ㎍ for lentivirus production. Then, the lentiviral including 4-1BBL and OX40L was used to deliver CT26 mouse tumor cells to establish optimal delivery conditions according to the amount of virus. The transduction efficiency is maximal at 500 μL volume of lentiviral stock without change in cell shape or growth rate. CT26-4-1BBL, CT26-OX40L significantly inhibited the tumor growth compare with CT26-WT or CT26-β-gal cell line. These data showed the possibility the use of genetically modified tumor cells with costimulatory molecule as cancer immunotherapy agent.


Supported by : National Research Foundation of Korea (NRF)


  1. Allahverdiyev A, Tari G, Bagirova M, Abamor ES. Current approaches in development of immunotherapeutic vaccines for breast cancer. J Breast Cancer. 2018. 21: 343-353.
  2. Bukczynski J, Wen T, Ellefsen K, Gauldie J, Watts TH. Costimulatory ligand 4-1bbl (cd137l) as an efficient adjuvant for human antiviral cytotoxic t cell responses. Proc Natl Acad Sci U S A. 2004. 101: 1291-1296.
  3. Cheuk AT, Mufti GJ, Guinn BA. Role of 4-1bb:4-1bb ligand in cancer immunotherapy. Cancer Gene Ther. 2004. 11: 215-226.
  4. Chiang CL, Coukos G, Kandalaft LE. Whole tumor antigen vaccines: Where are we? Vaccines (Basel). 2015. 3: 344-372.
  5. Couch M, Saunders JK, O'Malley BW, Jr., Pardoll D, Jaffee E. Genetically engineered tumor cell vaccine in a head and neck cancer model. Laryngoscope. 2003. 113: 552-556.
  6. Croft M, So T, Duan W, Soroosh P. The significance of ox40 and ox40l to t-cell biology and immune disease. Immunol Rev. 2009. 229: 173-191.
  7. Curry WT, Jr., Gorrepati R, Piesche M, Sasada T, Agarwalla P, Jones PS, Gerstner ER, Golby AJ, Batchelor TT, Wen PY, Mihm MC, Dranoff G. Vaccination with irradiated autologous tumor cells mixed with irradiated gm-k562 cells stimulates antitumor immunity and t lymphocyte activation in patients with recurrent malignant glioma. Clin Cancer Res. 2016. 22: 2885-2896.
  8. de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: From autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother. 2008. 57: 1569-1577.
  9. Deng J, Zhao S, Zhang X, Jia K, Wang H, Zhou C, He Y. Ox40 (cd134) and ox40 ligand, important immune checkpoints in cancer. Onco Targets Ther. 2019. 12: 7347-7353.
  10. Dillman RO, Cornforth AN, Nistor GI, McClay EF, Amatruda TT, Depriest C. Randomized phase ii trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses. J Immunother Cancer. 2018. 6: 19.
  11. Eager R, Nemunaitis J. Gm-csf gene-transduced tumor vaccines. Mol Ther. 2005. 12: 18-27.
  12. Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhasz E, Ramlau R, van den Heuvel MM, Lal R, Kloecker GH, Eaton KD, Chu Q, Dunlop DJ, Jain M, Garon EB, Davis CS, Carrier E, Moses SC, Shawler DL, Fakhrai H. A phase iii study of belagenpumatucel-l, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer. 2015. 51: 2321-2329.
  13. Goldman B, DeFrancesco L. The cancer vaccine roller coaster. Nat Biotechnol. 2009. 27: 129-139.
  14. Hanna MG, Jr. Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer. Hum Vaccin Immunother. 2012. 8: 1156-1160.
  15. Hege KM, Jooss K, Pardoll D. Gm-csf gene-modifed cancer cell immunotherapies: Of mice and men. Int Rev Immunol. 2006. 25: 321-352.
  16. Keenan BP, Jaffee EM. Whole cell vaccines--past progress and future strategies. Semin Oncol. 2012. 39: 276-286.
  17. Kim HS, Kim-Schulze S, Kim DW, Kaufman HL. Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1bb ligand. Cancer Res. 2009. 69: 8516-8525.
  18. Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med. 2000. 191: 1699-1708.
  19. Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel). 2011. 3: 3856-3893.
  20. Lipson EJ, Sharfman WH, Chen S, McMiller TL, Pritchard TS, Salas JT, Sartorius-Mergenthaler S, Freed I, Ravi S, Wang H, Luber B, Sproul JD, Taube JM, Pardoll DM, Topalian SL. Safety and immunologic correlates of melanoma gvax, a gmcsf secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J Transl Med. 2015. 13: 214.
  21. Luo L, Lv M, Zhuang X, Zhang Q, Qiao T. Irradiation increases the immunogenicity of lung cancer cells and irradiationbased tumor cell vaccine elicits tumor-specific t cell responses in vivo. Onco Targets Ther. 2019. 12: 3805-3815.
  22. Madireddi S, Schabowsky RH, Srivastava AK, Sharma RK, Yolcu ES, Shirwan H. Sa-4-1bbl costimulation inhibits conversion of conventional cd4+ t cells into cd4+ foxp3+ t regulatory cells by production of ifn-gamma. PLoS One. 2012. 7: e42459.
  23. Malamas AS, Hammond SA, Schlom J, Hodge JW. Combination therapy with an ox40l fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer. Oncotarget. 2017. 8: 90825-90841.
  24. May KF, Jr., Chen L, Zheng P, Liu Y. Anti-4-1bb monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific cd8+ t cells. Cancer Res. 2002. 62: 3459-3465.
  25. Miguel A, Herrero MJ, Sendra L, Botella R, Algas R, Sanchez M, Alino SF. Comparative antitumor effect among gm-csf, il-12 and gm-csf+il-12 genetically modified tumor cell vaccines. Cancer Gene Ther. 2013. 20: 576-581.
  26. Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, Fox B, Jablons D, Aimi J, Lin A, Hege K. Phase 1/2 trial of autologous tumor mixed with an allogeneic gvax vaccine in advancedstage non-small-cell lung cancer. Cancer Gene Ther. 2006. 13: 555-562.
  27. Pan RY, Chung WH, Chu MT, Chen SJ, Chen HC, Zheng L, Hung SI. Recent development and clinical application of cancer vaccine: Targeting neoantigens. J Immunol Res. 2018. 2018: 4325874.
  28. Perica K, Varela JC, Oelke M, Schneck J. Adoptive t cell immunotherapy for cancer. Rambam Maimonides Med J. 2015. 6: e0004.
  29. Si C, Xu M, Lu M, Yu Y, Yang M, Yan M, Zhou L, Yang X. In vivo antitumor activity evaluation of cancer vaccines prepared by various antigen forms in a murine hepatocellular carcinoma model. Oncol Lett. 2017. 14: 7391-7397.
  30. Srivatsan S, Patel JM, Bozeman EN, Imasuen IE, He S, Daniels D, Selvaraj P. Allogeneic tumor cell vaccines: The promise and limitations in clinical trials. Hum Vaccin Immunother. 2014. 10: 52-63.
  31. Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, Sadelain M. T cell-encoded cd80 and 4-1bbl induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007. 13: 1440-1449.
  32. Tang Y, Garson K, Li L, Vanderhyden BC. Optimization of lentiviral vector production using polyethylenimine-mediated transfection. Oncol Lett. 2015. 9: 55-62.
  33. van Willigen WW, Bloemendal M, Gerritsen WR, Schreibelt G, de Vries IJM, Bol KF. Dendritic cell cancer therapy: Vaccinating the right patient at the right time. Front Immunol. 2018. 9: 2265.
  34. Vermaelen K. Vaccine strategies to improve anti-cancer cellular immune responses. Front Immunol. 2019. 10: 8.
  35. Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1bb. Mol Cancer Ther. 2012. 11: 1062-1070.
  36. Wang T, Wang D, Yu H, Feng B, Zhou F, Zhang H, Zhou L, Jiao S, Li Y. A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors. Nat Commun. 2018. 9: 1532.
  37. Webb GJ, Hirschfield GM, Lane PJ. Ox40, ox40l and autoimmunity: A comprehensive review. Clin Rev Allergy Immunol. 2016. 50: 312-332.
  38. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet. 2009. 373: 1033-1040.
  39. Zhang H, Merchant MS, Chua KS, Khanna C, Helman LJ, Telford B, Ward Y, Summers J, Toretsky J, Thomas EK, June CH, Mackall CL. Tumor expression of 4-1bb ligand sustains tumor lytic t cells. Cancer Biol Ther. 2003. 2: 579-586.